BR112020009520A2 - métodos de tratamento, tradipitant, e, composição farmacêutica - Google Patents

métodos de tratamento, tradipitant, e, composição farmacêutica Download PDF

Info

Publication number
BR112020009520A2
BR112020009520A2 BR112020009520-6A BR112020009520A BR112020009520A2 BR 112020009520 A2 BR112020009520 A2 BR 112020009520A2 BR 112020009520 A BR112020009520 A BR 112020009520A BR 112020009520 A2 BR112020009520 A2 BR 112020009520A2
Authority
BR
Brazil
Prior art keywords
tradipitant
fact
day
gastroparesis
disease
Prior art date
Application number
BR112020009520-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Mihael H. Polymeropoulos
Gunther Birznieks
Original Assignee
Vanda Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc. filed Critical Vanda Pharmaceuticals Inc.
Publication of BR112020009520A2 publication Critical patent/BR112020009520A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112020009520-6A 2017-11-17 2018-11-16 métodos de tratamento, tradipitant, e, composição farmacêutica BR112020009520A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762587681P 2017-11-17 2017-11-17
US62/587,681 2017-11-17
PCT/US2018/061593 WO2019099883A1 (en) 2017-11-17 2018-11-16 Method of treatment of gastrointestinal diseases with tradipitant

Publications (1)

Publication Number Publication Date
BR112020009520A2 true BR112020009520A2 (pt) 2020-11-03

Family

ID=64734107

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020009520-6A BR112020009520A2 (pt) 2017-11-17 2018-11-16 métodos de tratamento, tradipitant, e, composição farmacêutica

Country Status (19)

Country Link
US (4) US20200030307A1 (https=)
EP (1) EP3710000B1 (https=)
JP (1) JP7306614B2 (https=)
KR (2) KR102864285B1 (https=)
CN (2) CN119074729A (https=)
AU (1) AU2018367623B2 (https=)
BR (1) BR112020009520A2 (https=)
CA (1) CA3081582A1 (https=)
CL (1) CL2020001290A1 (https=)
DK (1) DK3710000T3 (https=)
ES (1) ES3032138T3 (https=)
FI (1) FI3710000T3 (https=)
HR (1) HRP20250615T1 (https=)
HU (1) HUE071527T2 (https=)
IL (1) IL274541B2 (https=)
MX (1) MX2020005167A (https=)
PT (1) PT3710000T (https=)
SI (1) SI3710000T1 (https=)
WO (1) WO2019099883A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2824552T3 (es) * 2015-03-04 2021-05-12 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant
CA3101210A1 (en) * 2018-06-08 2019-12-12 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
HUE070000T2 (hu) * 2018-09-28 2025-04-28 Vanda Pharmaceuticals Inc Tradipitant alkalmazása utazási betegségben
WO2020117811A1 (en) 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
JP7791832B2 (ja) 2020-03-26 2025-12-24 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる下気道感染症の治療
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
AU2023413130A1 (en) 2022-12-21 2025-06-05 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003230829B8 (en) 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
BRPI0415010B8 (pt) * 2003-10-24 2021-05-25 Lilly Co Eli formas cristalinas iv e v de {2-[1-(3,5-bis-trifluorometilbenzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il)-(2-clorofenil)-metanona, (2-clorofenil)-[2-(2-hidróxi-2-piridin-4-il-vinil)piridin-3-il]metanona, seus processos de preparação, e composição farmacêutica sólida
BRPI0721069A2 (pt) 2006-12-20 2014-02-04 Lilly Co Eli Intermediários e processo útil na preparação de {2-[1-(3,5-bis-trifluorometil-benzil)-5-piridin-4-il-1h[1,2, 3]triazol-4-il]-piridin-3-il}-2-clorofenil)-metanona
ES2623503T3 (es) * 2009-11-18 2017-07-11 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos mediados centralmente
ES2824552T3 (es) * 2015-03-04 2021-05-12 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant
CN115531553A (zh) * 2015-12-22 2022-12-30 武田药品工业株式会社 内体g蛋白-偶联的受体的三部分调节剂

Also Published As

Publication number Publication date
CN119074729A (zh) 2024-12-06
MX2020005167A (es) 2020-08-20
US20210330656A1 (en) 2021-10-28
CA3081582A1 (en) 2019-05-23
KR20250140655A (ko) 2025-09-25
ES3032138T3 (en) 2025-07-15
WO2019099883A1 (en) 2019-05-23
DK3710000T3 (da) 2025-06-16
US20230390269A1 (en) 2023-12-07
KR102864285B1 (ko) 2025-09-24
JP2021503480A (ja) 2021-02-12
KR20200088346A (ko) 2020-07-22
US20210093621A1 (en) 2021-04-01
HRP20250615T1 (hr) 2025-07-18
IL274541B1 (en) 2024-06-01
IL274541A (en) 2020-06-30
JP7306614B2 (ja) 2023-07-11
IL274541B2 (en) 2024-10-01
AU2018367623A1 (en) 2020-05-21
HUE071527T2 (hu) 2025-09-28
US20200030307A1 (en) 2020-01-30
PT3710000T (pt) 2025-05-29
CN111343981A (zh) 2020-06-26
EP3710000A1 (en) 2020-09-23
SI3710000T1 (sl) 2025-07-31
EP3710000B1 (en) 2025-04-23
FI3710000T3 (fi) 2025-07-03
RU2020119259A (ru) 2021-12-17
CL2020001290A1 (es) 2020-11-13
NZ764107A (en) 2024-07-05
AU2018367623B2 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
US20230390269A1 (en) Method of treatment with tradipitant
De Ponti Pharmacology of serotonin: what a clinician should know
US20220096449A1 (en) Method of treatment with tradipitant
US20230134844A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112020026062B1 (pt) Compostos derivados de benzodiazepina ou um sal farmaceuticamente aceitavel, isômero ou combinação dos mesmos, composição farmacêutica compreendendo os mesmos e usos dos mesmos para o tratamento de comprometimento cognitivo, câncer cerebral e psicose da doença de parkinson
US20240285588A1 (en) Use of tradipitant in motion sickness
US10821099B2 (en) Use of tradipitant in motion sickness
CN115175911A (zh) 用于治疗认知损害的苯二氮䓬衍生物、组合物和方法
EA018927B1 (ru) Способ лечения когнитивного расстройства, ассоциированного с шизофренией
JP2001502311A (ja) 抗鬱及び/又は抗不安薬としてのcns浸透性nk―1受容体拮抗薬
CN116075302A (zh) GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法
Prommer Aprepitant (EMEND) the role of substance P in nausea and vomiting
RU2797248C2 (ru) Способ лечения заболеваний желудочно-кишечного тракта традипитантом
BR112019012821A2 (pt) derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20240299373A1 (en) Improved use of tradipitant in motion sickness
WO2023019084A1 (en) Treatment of gastric accommodation with tradipitant
BR122023024430A2 (pt) Compostos derivados de benzodiazepina, composição farmacêutica compreendendo os mesmos e uso destes para o tratamento de défice cognitivo associado a um distúrbio do sistema nervoso central (snc)
BR112017027515B1 (pt) Derivados de benzodiazepina, composições e métodos para tratamento de défice cognitivo
BR112016014564B1 (pt) Compostos derivados de benzodiazepina, composição farmacêutica compreendendo ditos compostos e uso da mesma para o tratamento de deficiência cognitiva associada a um distúrbio do sistema nervoso central
BR122023024430B1 (pt) Compostos derivados de benzodiazepina, composição farmacêutica compreendendo os mesmos e uso destes para o tratamento de défice cognitivo associado a um distúrbio do sistema nervoso central (snc)

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]